Evidence map›Paper›PMID 34106589›Full record

Observational studyMedicine2021

Comparison of liver biochemical abnormality between COVID-19 patients with liver cirrhosis versus COVID-19 alone and liver cirrhosis alone: A STROBE observational study.

Yang An, Zhuang Ma, Xiaozhong Guo, Yufu Tang, Hao Meng, Hao Yu, Chengfei Peng, Guiyang Chu, Xinwei Wang, Yue Teng and 7 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 4 countries.

Yang AnCOVID-19 Study Group, General Hospital of Northern Theater Command.
Zhuang MaCOVID-19 Study Group, General Hospital of Northern Theater Command.
Xiaozhong GuoCOVID-19 Study Group, General Hospital of Northern Theater Command.
Yufu TangCOVID-19 Study Group, General Hospital of Northern Theater Command.
Hao MengCOVID-19 Study Group, General Hospital of Northern Theater Command.
Hao YuCOVID-19 Study Group, General Hospital of Northern Theater Command.
Chengfei PengCOVID-19 Study Group, General Hospital of Northern Theater Command.
Guiyang ChuCOVID-19 Study Group, General Hospital of Northern Theater Command.
Xinwei WangCOVID-19 Study Group, General Hospital of Northern Theater Command.
Yue TengCOVID-19 Study Group, General Hospital of Northern Theater Command.
Quanyu ZhangCOVID-19 Study Group, General Hospital of Northern Theater Command.
Tianyi ZhuCOVID-19 Study Group, General Hospital of Northern Theater Command.
Bing WangCOVID-19 Study Group, General Hospital of Northern Theater Command.
Zhenhua TongCOVID-19 Study Group, General Hospital of Northern Theater Command.
Haitao ZhaoCOVID-19 Study Group, General Hospital of Northern Theater Command.
Hui LuCOVID-19 Study Group, General Hospital of Northern Theater Command.
Xingshun QiCOVID-19 Study Group, General Hospital of Northern Theater Command.ORCID 0000-0002-9448-6739
Associated Press · USCommand Hospital · INShenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCoronavirus disease (COVID-19) patients frequently develop liver biochemical abnormality. However, liver biochemical abnormality in COVID-19 patients with liver cirrhosis is under-recognized.Patients hospitalized during COVID-19 pandemic in China (ie, from February to April 2020) were screened. All of 17 COVID-19 patients with liver cirrhosis consecutively admitted to the Wuhan Huoshenshan Hospital were identified. Meanwhile, 17 age-, sex-, and severity-matched COVID-19 patients without liver cirrhosis admitted to this hospital were selected as a control group; all of 14 cirrhotic patients without COVID-19 consecutively admitted to the Department of Gastroenterology of the General Hospital of Northern Theater Command were selected as another control group. Incidence of liver biochemical abnormality and decompensated events were primarily compared.Among the COVID-19 patients with liver cirrhosis, the incidence of liver biochemical abnormality at admission and during hospitalization were 76.50% and 84.60%, respectively; 7 (41.20%) had decompensated events at admission; 1 was transferred to intensive care unit due to gastrointestinal bleeding. Among the COVID-19 patients without liver cirrhosis, the incidence of liver biochemical abnormality at admission and during hospitalization were 58.80% (P = .271) and 60.00% (P = .150), respectively. Among the cirrhotic patients without COVID-19, the incidence of liver biochemical abnormality at admission and during hospitalization were 69.20% (P = .657) and 81.80% (P = .855), respectively; 11 (78.60%) had decompensated events at admission (P = .036). None died during hospitalization among the three groups.Liver biochemical abnormality is common in COVID-19 patients with liver cirrhosis. Management of decompensated events in cirrhotic patients without COVID-19 should not be neglected during COVID-19 pandemic.

Indexed as

Liver Function TestsAdultAgedAged, 80 and overCase-Control StudiesChinaCOVID-19FemaleHumansIntensive Care UnitsLiver CirrhosisMaleMiddle AgedPandemicsRisk FactorsSARS-CoV-2

Identifiers

PMID34106589
PMCPMC8133226
OpenAlexW3163592288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.